InsidersTradesSigma
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Discover the full record of transactions filed by Shenouda Maged. Director active across 2 companies, notably Relmada Therapeutics, INC.. In total, 6 filings have been published. Breakdown: 5 buys · 0 sell. Total volume traded: €1.1m. History available since 29 January 2024. The latest transaction was disclosed on 15 December 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations
Shenouda Maged is a declarant linked to Relmada Therapeutics, INC. as Chief Financial Officer and to Protea Biosciences Group, Inc. as Director. Across 6 filings in total, the 6 sampled filings cover the period from 2016-01-07 to 2025-12-16 and show only acquisitions, with buy volume of EUR 1073728 and no sales reported.